Edward Ashwood
Concepts (364)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prenatal Diagnosis | 14 | 2021 | 201 | 1.330 |
Why?
| | Amniotic Fluid | 16 | 2006 | 96 | 1.080 |
Why?
| | Antigens, Fungal | 4 | 2011 | 28 | 0.960 |
Why?
| | Histoplasma | 3 | 2009 | 12 | 0.880 |
Why?
| | Immunoenzyme Techniques | 4 | 2009 | 219 | 0.860 |
Why?
| | Laboratories | 8 | 2020 | 113 | 0.760 |
Why?
| | Fetal Organ Maturity | 14 | 2004 | 27 | 0.710 |
Why?
| | Histoplasmosis | 3 | 2011 | 17 | 0.700 |
Why?
| | Trisomy | 4 | 2020 | 80 | 0.570 |
Why?
| | Chemistry, Clinical | 6 | 2014 | 12 | 0.540 |
Why?
| | Pathology, Clinical | 7 | 2014 | 36 | 0.530 |
Why?
| | Bilirubin | 3 | 2006 | 97 | 0.520 |
Why?
| | Down Syndrome | 9 | 2021 | 496 | 0.510 |
Why?
| | Aspartate Aminotransferases | 1 | 2015 | 90 | 0.470 |
Why?
| | Alanine Transaminase | 1 | 2015 | 157 | 0.460 |
Why?
| | Clinical Laboratory Techniques | 5 | 2013 | 97 | 0.430 |
Why?
| | DNA | 4 | 2020 | 1459 | 0.430 |
Why?
| | Fetal Diseases | 2 | 2013 | 173 | 0.420 |
Why?
| | Pathology | 2 | 2010 | 24 | 0.420 |
Why?
| | Chromosome Disorders | 1 | 2013 | 43 | 0.420 |
Why?
| | alpha 1-Antitrypsin Deficiency | 5 | 2013 | 67 | 0.400 |
Why?
| | Lung | 14 | 2004 | 4060 | 0.390 |
Why?
| | Liver Diseases | 1 | 2015 | 315 | 0.380 |
Why?
| | alpha-Fetoproteins | 6 | 2013 | 46 | 0.360 |
Why?
| | Phosphatidylcholines | 12 | 2001 | 147 | 0.360 |
Why?
| | Pregnancy | 28 | 2021 | 6763 | 0.350 |
Why?
| | Medical Laboratory Personnel | 1 | 2010 | 7 | 0.350 |
Why?
| | Serpins | 1 | 2010 | 31 | 0.330 |
Why?
| | Antibodies, Fungal | 1 | 2009 | 9 | 0.320 |
Why?
| | Fluorescence Polarization | 10 | 1994 | 37 | 0.320 |
Why?
| | alpha 1-Antitrypsin | 4 | 2013 | 108 | 0.320 |
Why?
| | Sphingomyelins | 11 | 2001 | 33 | 0.310 |
Why?
| | Delivery of Health Care | 2 | 2015 | 951 | 0.300 |
Why?
| | Pancreatic Function Tests | 1 | 2008 | 4 | 0.300 |
Why?
| | Pancreatic Elastase | 1 | 2008 | 58 | 0.290 |
Why?
| | Antigens, Neoplasm | 1 | 2010 | 319 | 0.280 |
Why?
| | Specimen Handling | 7 | 2002 | 183 | 0.280 |
Why?
| | Neural Tube Defects | 3 | 2021 | 64 | 0.270 |
Why?
| | Chloroform | 1 | 2006 | 4 | 0.270 |
Why?
| | Pancreas | 1 | 2008 | 329 | 0.240 |
Why?
| | Feces | 1 | 2008 | 484 | 0.230 |
Why?
| | Humans | 78 | 2024 | 137585 | 0.220 |
Why?
| | Phosphatidylglycerols | 6 | 2001 | 24 | 0.210 |
Why?
| | Renin | 1 | 2003 | 35 | 0.210 |
Why?
| | Biomarkers, Tumor | 1 | 2010 | 1276 | 0.200 |
Why?
| | Pulmonary Surfactants | 3 | 2004 | 106 | 0.200 |
Why?
| | Reagent Kits, Diagnostic | 5 | 2015 | 42 | 0.200 |
Why?
| | Rabbits | 3 | 2009 | 794 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2010 | 852 | 0.190 |
Why?
| | Creatinine | 4 | 2013 | 499 | 0.180 |
Why?
| | Reference Values | 6 | 2013 | 816 | 0.180 |
Why?
| | Quality Control | 5 | 2008 | 172 | 0.170 |
Why?
| | Internship and Residency | 4 | 2014 | 1147 | 0.170 |
Why?
| | Reproducibility of Results | 13 | 2015 | 3284 | 0.160 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2020 | 43 | 0.150 |
Why?
| | Phospholipids | 4 | 2001 | 223 | 0.150 |
Why?
| | Vaccines | 1 | 2024 | 406 | 0.150 |
Why?
| | Blood Specimen Collection | 4 | 2003 | 41 | 0.140 |
Why?
| | Laboratories, Hospital | 3 | 2013 | 15 | 0.140 |
Why?
| | Clinical Laboratory Information Systems | 3 | 1992 | 7 | 0.140 |
Why?
| | Fluorescent Dyes | 6 | 1993 | 321 | 0.140 |
Why?
| | Amniocentesis | 5 | 2013 | 25 | 0.140 |
Why?
| | Female | 35 | 2021 | 73304 | 0.140 |
Why?
| | Phenotype | 4 | 2013 | 3196 | 0.130 |
Why?
| | Lead | 1 | 1997 | 64 | 0.130 |
Why?
| | Utah | 3 | 2014 | 69 | 0.130 |
Why?
| | Referral and Consultation | 2 | 2014 | 786 | 0.130 |
Why?
| | Photosensitivity Disorders | 1 | 1996 | 9 | 0.130 |
Why?
| | Hepacivirus | 3 | 2005 | 261 | 0.130 |
Why?
| | Capillaries | 1 | 1997 | 108 | 0.130 |
Why?
| | Vitamin B 12 | 1 | 1997 | 128 | 0.130 |
Why?
| | Porphyrins | 1 | 1996 | 23 | 0.130 |
Why?
| | Cryopreservation | 1 | 1997 | 100 | 0.130 |
Why?
| | Folic Acid | 1 | 1997 | 186 | 0.120 |
Why?
| | Clinical Laboratory Services | 1 | 2015 | 8 | 0.120 |
Why?
| | Blood Chemical Analysis | 2 | 2008 | 99 | 0.120 |
Why?
| | Altitude | 1 | 2000 | 488 | 0.120 |
Why?
| | Maternal Serum Screening Tests | 1 | 2015 | 3 | 0.120 |
Why?
| | United States | 13 | 2021 | 14841 | 0.110 |
Why?
| | Aneuploidy | 1 | 2015 | 89 | 0.110 |
Why?
| | Hepatitis, Viral, Human | 2 | 2007 | 25 | 0.110 |
Why?
| | Curriculum | 2 | 2006 | 992 | 0.100 |
Why?
| | Blood Preservation | 1 | 1997 | 285 | 0.100 |
Why?
| | Infant, Newborn | 10 | 2008 | 6079 | 0.100 |
Why?
| | Legislation, Medical | 1 | 2013 | 11 | 0.100 |
Why?
| | Evaluation Studies as Topic | 7 | 2000 | 180 | 0.100 |
Why?
| | Abortion, Induced | 1 | 2015 | 105 | 0.100 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 1993 | 17 | 0.100 |
Why?
| | Government Regulation | 1 | 2013 | 54 | 0.100 |
Why?
| | Isoquinolines | 1 | 1993 | 43 | 0.100 |
Why?
| | Pregnancy Trimester, Second | 2 | 2021 | 80 | 0.100 |
Why?
| | Neuromuscular Junction | 1 | 1993 | 57 | 0.100 |
Why?
| | Kidney Function Tests | 1 | 2013 | 160 | 0.100 |
Why?
| | Medical Informatics | 1 | 1993 | 101 | 0.100 |
Why?
| | Embryonic and Fetal Development | 1 | 1992 | 97 | 0.100 |
Why?
| | Chlorine | 1 | 1992 | 61 | 0.100 |
Why?
| | Genetic Testing | 2 | 2015 | 460 | 0.100 |
Why?
| | Automation | 2 | 2002 | 95 | 0.100 |
Why?
| | Sensitivity and Specificity | 7 | 2013 | 1946 | 0.090 |
Why?
| | Mass Spectrometry | 2 | 2011 | 739 | 0.090 |
Why?
| | Software Validation | 1 | 1992 | 10 | 0.090 |
Why?
| | Arsenic | 1 | 1992 | 64 | 0.090 |
Why?
| | Observer Variation | 3 | 2009 | 343 | 0.090 |
Why?
| | Chlorides | 1 | 1992 | 136 | 0.090 |
Why?
| | RNA, Viral | 4 | 2005 | 656 | 0.090 |
Why?
| | Proteinuria | 1 | 2011 | 97 | 0.090 |
Why?
| | Inclusion Bodies | 2 | 2001 | 28 | 0.090 |
Why?
| | Consultants | 1 | 2011 | 13 | 0.090 |
Why?
| | Glomerular Filtration Rate | 2 | 2013 | 746 | 0.090 |
Why?
| | Immunoglobulin G | 2 | 2024 | 893 | 0.090 |
Why?
| | Fluorescence Polarization Immunoassay | 1 | 1990 | 1 | 0.090 |
Why?
| | Pregnancy Complications | 2 | 1993 | 527 | 0.080 |
Why?
| | Hospitals | 1 | 2015 | 691 | 0.080 |
Why?
| | Materials Testing | 1 | 1992 | 356 | 0.080 |
Why?
| | Adult | 15 | 2015 | 37929 | 0.080 |
Why?
| | Inhibins | 2 | 2013 | 44 | 0.080 |
Why?
| | History, 21st Century | 1 | 2010 | 213 | 0.080 |
Why?
| | Prenatal Care | 1 | 1992 | 294 | 0.080 |
Why?
| | Fetal Monitoring | 1 | 1989 | 15 | 0.080 |
Why?
| | False Positive Reactions | 2 | 2007 | 115 | 0.080 |
Why?
| | Pathology, Surgical | 1 | 2009 | 10 | 0.080 |
Why?
| | Chromatography, Liquid | 1 | 2011 | 433 | 0.080 |
Why?
| | Cross Reactions | 2 | 2007 | 133 | 0.080 |
Why?
| | Water-Electrolyte Balance | 1 | 1988 | 34 | 0.070 |
Why?
| | Mass Screening | 2 | 2015 | 1287 | 0.070 |
Why?
| | Nickel | 1 | 1988 | 62 | 0.070 |
Why?
| | Interprofessional Relations | 1 | 2011 | 283 | 0.070 |
Why?
| | Ion Channels | 1 | 1988 | 133 | 0.070 |
Why?
| | Pregnancy Trimester, First | 2 | 2021 | 140 | 0.070 |
Why?
| | Kidney Tubules | 1 | 1988 | 117 | 0.070 |
Why?
| | Oxygen | 1 | 1992 | 931 | 0.070 |
Why?
| | Respiratory Distress Syndrome, Newborn | 3 | 2004 | 106 | 0.070 |
Why?
| | Hepatitis, Autoimmune | 1 | 2007 | 20 | 0.070 |
Why?
| | Clinical Chemistry Tests | 1 | 2006 | 11 | 0.070 |
Why?
| | Gestational Age | 5 | 2013 | 910 | 0.060 |
Why?
| | Reference Standards | 2 | 2004 | 186 | 0.060 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 617 | 0.060 |
Why?
| | Solvents | 1 | 2006 | 109 | 0.060 |
Why?
| | Antibodies | 1 | 2008 | 410 | 0.060 |
Why?
| | Pediatrics | 2 | 2006 | 1101 | 0.060 |
Why?
| | DNA, Viral | 2 | 2005 | 364 | 0.060 |
Why?
| | Child | 8 | 2013 | 21935 | 0.060 |
Why?
| | Conflict of Interest | 1 | 2007 | 130 | 0.060 |
Why?
| | Actins | 2 | 2007 | 416 | 0.060 |
Why?
| | Proteins | 1 | 2011 | 1009 | 0.060 |
Why?
| | Animals | 9 | 2009 | 36940 | 0.060 |
Why?
| | Hepatitis B virus | 1 | 2005 | 40 | 0.060 |
Why?
| | Data Collection | 2 | 2005 | 673 | 0.060 |
Why?
| | Child, Preschool | 5 | 2013 | 11074 | 0.060 |
Why?
| | Algorithms | 2 | 2013 | 1704 | 0.050 |
Why?
| | Hematologic Tests | 1 | 2004 | 22 | 0.050 |
Why?
| | Monte Carlo Method | 2 | 2015 | 148 | 0.050 |
Why?
| | Hyperbilirubinemia | 1 | 2003 | 13 | 0.050 |
Why?
| | Infant | 4 | 2013 | 9465 | 0.050 |
Why?
| | Teaching | 1 | 2006 | 224 | 0.050 |
Why?
| | Blood Gas Analysis | 1 | 1983 | 74 | 0.050 |
Why?
| | Spectrophotometry | 1 | 2003 | 61 | 0.050 |
Why?
| | Mathematics | 1 | 1983 | 103 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2002 | 976 | 0.050 |
Why?
| | Middle Aged | 7 | 2015 | 33479 | 0.050 |
Why?
| | Central Nervous System Diseases | 1 | 2003 | 69 | 0.050 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 591 | 0.050 |
Why?
| | Antibodies, Heterophile | 1 | 2001 | 14 | 0.050 |
Why?
| | Risk | 3 | 2007 | 912 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 1430 | 0.040 |
Why?
| | Sarcoidosis | 1 | 2003 | 159 | 0.040 |
Why?
| | HIV Antibodies | 1 | 2001 | 62 | 0.040 |
Why?
| | Isoelectric Focusing | 2 | 2013 | 34 | 0.040 |
Why?
| | Aged | 5 | 2013 | 23961 | 0.040 |
Why?
| | Postoperative Complications | 1 | 1993 | 2654 | 0.040 |
Why?
| | Acute Disease | 2 | 2007 | 1007 | 0.040 |
Why?
| | Immunoassay | 1 | 2001 | 115 | 0.040 |
Why?
| | HIV Seropositivity | 1 | 2001 | 125 | 0.040 |
Why?
| | Maternal Age | 2 | 2013 | 129 | 0.040 |
Why?
| | Trisomy 13 Syndrome | 1 | 2020 | 3 | 0.040 |
Why?
| | Trisomy 18 Syndrome | 1 | 2020 | 6 | 0.040 |
Why?
| | Young Adult | 3 | 2013 | 13209 | 0.040 |
Why?
| | Genotype | 4 | 2007 | 1916 | 0.040 |
Why?
| | Estriol | 2 | 2013 | 8 | 0.040 |
Why?
| | Prospective Studies | 5 | 1993 | 7604 | 0.040 |
Why?
| | Adolescent | 4 | 2013 | 21513 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2024 | 625 | 0.040 |
Why?
| | Chorionic Gonadotropin | 2 | 2013 | 80 | 0.040 |
Why?
| | Autoantibodies | 1 | 2007 | 1496 | 0.040 |
Why?
| | Polymerase Chain Reaction | 3 | 2007 | 1062 | 0.040 |
Why?
| | Time Factors | 3 | 1997 | 6828 | 0.030 |
Why?
| | Syndrome | 1 | 1998 | 358 | 0.030 |
Why?
| | Predictive Value of Tests | 4 | 2005 | 2031 | 0.030 |
Why?
| | Health Personnel | 1 | 2024 | 710 | 0.030 |
Why?
| | Hepatitis C | 1 | 2000 | 271 | 0.030 |
Why?
| | Drug Storage | 1 | 1997 | 57 | 0.030 |
Why?
| | Centrifugation | 2 | 1988 | 30 | 0.030 |
Why?
| | Hand Disinfection | 1 | 1997 | 27 | 0.030 |
Why?
| | History, 20th Century | 1 | 1998 | 325 | 0.030 |
Why?
| | Drug Stability | 1 | 1997 | 167 | 0.030 |
Why?
| | Veins | 1 | 1997 | 63 | 0.030 |
Why?
| | Congresses as Topic | 1 | 1998 | 233 | 0.030 |
Why?
| | Porphobilinogen | 1 | 1996 | 1 | 0.030 |
Why?
| | Uroporphyrins | 1 | 1996 | 1 | 0.030 |
Why?
| | Porphyria Cutanea Tarda | 1 | 1996 | 1 | 0.030 |
Why?
| | Coproporphyrins | 1 | 1996 | 3 | 0.030 |
Why?
| | Membrane Fluidity | 3 | 1990 | 11 | 0.030 |
Why?
| | Coronary Disease | 1 | 1998 | 385 | 0.030 |
Why?
| | Male | 7 | 2013 | 67762 | 0.030 |
Why?
| | Freezing | 2 | 1986 | 90 | 0.030 |
Why?
| | Hospital Administration | 1 | 2015 | 26 | 0.030 |
Why?
| | Retrospective Studies | 5 | 2014 | 15657 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 93 | 0.030 |
Why?
| | HIV-1 | 1 | 2001 | 864 | 0.030 |
Why?
| | Commerce | 1 | 2015 | 82 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2015 | 82 | 0.030 |
Why?
| | Health Care Reform | 1 | 2015 | 107 | 0.030 |
Why?
| | Ampyrone | 1 | 1994 | 1 | 0.030 |
Why?
| | Glycerol Kinase | 1 | 1994 | 1 | 0.030 |
Why?
| | Chromogenic Compounds | 1 | 1994 | 2 | 0.030 |
Why?
| | Glycerolphosphate Dehydrogenase | 1 | 1994 | 6 | 0.030 |
Why?
| | Phospholipase D | 1 | 1994 | 9 | 0.030 |
Why?
| | Microchemistry | 1 | 1994 | 20 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1996 | 597 | 0.030 |
Why?
| | Neutrophils | 2 | 1990 | 1238 | 0.030 |
Why?
| | Pregnancy Trimesters | 1 | 2013 | 19 | 0.030 |
Why?
| | Professional Competence | 1 | 2014 | 100 | 0.030 |
Why?
| | 4-Chloro-7-nitrobenzofurazan | 1 | 1993 | 4 | 0.030 |
Why?
| | Butyrylcholinesterase | 1 | 1993 | 2 | 0.030 |
Why?
| | In Vitro Techniques | 3 | 1990 | 1092 | 0.030 |
Why?
| | Cholinesterases | 1 | 1993 | 10 | 0.030 |
Why?
| | Cytological Techniques | 1 | 1993 | 27 | 0.030 |
Why?
| | Pentoxifylline | 2 | 1990 | 25 | 0.030 |
Why?
| | Vanadium | 1 | 1992 | 11 | 0.030 |
Why?
| | Education, Medical, Continuing | 1 | 2014 | 127 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 2 | 1990 | 136 | 0.020 |
Why?
| | Abortion, Spontaneous | 1 | 2013 | 105 | 0.020 |
Why?
| | Costs and Cost Analysis | 1 | 2013 | 213 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2000 | 1587 | 0.020 |
Why?
| | Albumins | 1 | 1992 | 114 | 0.020 |
Why?
| | Cell Separation | 1 | 1993 | 318 | 0.020 |
Why?
| | Systems Analysis | 1 | 1992 | 23 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2013 | 208 | 0.020 |
Why?
| | Health Care Costs | 1 | 2015 | 398 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 539 | 0.020 |
Why?
| | Catheterization, Swan-Ganz | 1 | 1990 | 9 | 0.020 |
Why?
| | Virulence Factors, Bordetella | 1 | 1990 | 20 | 0.020 |
Why?
| | Pertussis Toxin | 1 | 1990 | 26 | 0.020 |
Why?
| | Receptors, Lymphocyte Homing | 1 | 1990 | 16 | 0.020 |
Why?
| | Endothelium, Lymphatic | 1 | 1990 | 12 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2013 | 5778 | 0.020 |
Why?
| | Erythrocyte Membrane | 1 | 1990 | 55 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2011 | 180 | 0.020 |
Why?
| | Program Development | 2 | 2002 | 364 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 1994 | 1060 | 0.020 |
Why?
| | Security Measures | 1 | 1990 | 8 | 0.020 |
Why?
| | Theobromine | 1 | 1989 | 2 | 0.020 |
Why?
| | Information Systems | 1 | 1990 | 61 | 0.020 |
Why?
| | Calibration | 1 | 1990 | 146 | 0.020 |
Why?
| | Sodium | 1 | 1990 | 217 | 0.020 |
Why?
| | Hemolysis | 1 | 1990 | 206 | 0.020 |
Why?
| | Hypotonic Solutions | 1 | 1988 | 1 | 0.020 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1990 | 87 | 0.020 |
Why?
| | Blood Protein Electrophoresis | 1 | 2008 | 7 | 0.020 |
Why?
| | Pregnancy in Diabetics | 1 | 1991 | 123 | 0.020 |
Why?
| | Electrophoresis, Capillary | 1 | 2008 | 20 | 0.020 |
Why?
| | Risk Factors | 2 | 2013 | 10388 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 1988 | 38 | 0.020 |
Why?
| | Goldfish | 1 | 1988 | 30 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 1988 | 49 | 0.020 |
Why?
| | Cell Adhesion | 1 | 1990 | 466 | 0.020 |
Why?
| | Sodium Channels | 1 | 1988 | 65 | 0.020 |
Why?
| | Particle Size | 1 | 1990 | 394 | 0.020 |
Why?
| | Lymphocytes | 1 | 1990 | 397 | 0.020 |
Why?
| | Subcellular Fractions | 1 | 1988 | 82 | 0.020 |
Why?
| | Potassium Channels | 1 | 1988 | 151 | 0.020 |
Why?
| | Biomarkers | 2 | 2013 | 4149 | 0.020 |
Why?
| | Erythrocytes | 1 | 1993 | 700 | 0.020 |
Why?
| | Databases as Topic | 1 | 2007 | 67 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2011 | 706 | 0.020 |
Why?
| | Pregnancy, High-Risk | 1 | 1987 | 14 | 0.020 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 1987 | 10 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2007 | 51 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2008 | 404 | 0.020 |
Why?
| | Proteome | 1 | 2011 | 472 | 0.020 |
Why?
| | Pregnancy Outcome | 1 | 1989 | 416 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 165 | 0.020 |
Why?
| | Chromatography, Thin Layer | 1 | 1986 | 26 | 0.020 |
Why?
| | Gene Frequency | 1 | 2007 | 521 | 0.020 |
Why?
| | Muscle, Smooth | 1 | 2007 | 155 | 0.020 |
Why?
| | Fetus | 1 | 1990 | 806 | 0.020 |
Why?
| | Medical Staff, Hospital | 1 | 2006 | 83 | 0.020 |
Why?
| | Solutions | 1 | 1986 | 168 | 0.010 |
Why?
| | Amnion | 1 | 1985 | 28 | 0.010 |
Why?
| | Respiration Disorders | 1 | 1986 | 77 | 0.010 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 1991 | 641 | 0.010 |
Why?
| | Cattle | 2 | 2001 | 984 | 0.010 |
Why?
| | Ultracentrifugation | 1 | 2005 | 52 | 0.010 |
Why?
| | Societies, Medical | 1 | 2009 | 820 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1990 | 1242 | 0.010 |
Why?
| | Bacteriological Techniques | 1 | 2005 | 73 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 891 | 0.010 |
Why?
| | Hepatitis B | 1 | 2005 | 70 | 0.010 |
Why?
| | Child Health Services | 1 | 2006 | 184 | 0.010 |
Why?
| | Dimerization | 1 | 2004 | 199 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 2013 | 7635 | 0.010 |
Why?
| | Plasma | 1 | 2005 | 212 | 0.010 |
Why?
| | Neonatal Screening | 1 | 2004 | 169 | 0.010 |
Why?
| | Temperature | 1 | 1986 | 679 | 0.010 |
Why?
| | Body Temperature | 1 | 1983 | 222 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1983 | 560 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 1118 | 0.010 |
Why?
| | Goats | 1 | 2001 | 27 | 0.010 |
Why?
| | Serum Albumin, Bovine | 1 | 2001 | 64 | 0.010 |
Why?
| | Antibody Specificity | 1 | 2001 | 189 | 0.010 |
Why?
| | Microspheres | 1 | 2001 | 137 | 0.010 |
Why?
| | Likelihood Functions | 1 | 2001 | 144 | 0.010 |
Why?
| | Blood Glucose | 1 | 1990 | 2186 | 0.010 |
Why?
| | Antigens, Viral | 1 | 2001 | 178 | 0.010 |
Why?
| | Butanols | 2 | 1990 | 8 | 0.010 |
Why?
| | Structure-Activity Relationship | 2 | 1990 | 570 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2426 | 0.010 |
Why?
| | Placenta | 1 | 1985 | 750 | 0.010 |
Why?
| | Blotting, Western | 1 | 2001 | 1226 | 0.010 |
Why?
| | Sheep | 1 | 2001 | 856 | 0.010 |
Why?
| | Research Design | 1 | 2004 | 1139 | 0.010 |
Why?
| | Signal Transduction | 1 | 2011 | 5079 | 0.010 |
Why?
| | Cell Movement | 2 | 1990 | 967 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1991 | 3715 | 0.010 |
Why?
| | Chromatography | 1 | 1993 | 24 | 0.010 |
Why?
| | Cell Size | 1 | 1993 | 91 | 0.010 |
Why?
| | Cats | 1 | 1993 | 210 | 0.010 |
Why?
| | Horses | 1 | 1993 | 111 | 0.010 |
Why?
| | Dogs | 1 | 1993 | 413 | 0.010 |
Why?
| | Species Specificity | 1 | 1993 | 585 | 0.010 |
Why?
| | Fee Schedules | 1 | 1991 | 3 | 0.010 |
Why?
| | Melitten | 1 | 1990 | 3 | 0.010 |
Why?
| | Glycols | 1 | 1990 | 7 | 0.010 |
Why?
| | Elapid Venoms | 1 | 1990 | 18 | 0.010 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 1 | 1990 | 30 | 0.010 |
Why?
| | Germ-Free Life | 1 | 1990 | 34 | 0.010 |
Why?
| | Alcohols | 1 | 1990 | 27 | 0.010 |
Why?
| | 1-Butanol | 1 | 1990 | 2 | 0.010 |
Why?
| | Receptors, Leukocyte-Adhesion | 1 | 1990 | 5 | 0.010 |
Why?
| | Appointments and Schedules | 1 | 1991 | 89 | 0.010 |
Why?
| | Macrophage-1 Antigen | 1 | 1990 | 28 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1990 | 269 | 0.010 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 1990 | 81 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 1990 | 83 | 0.010 |
Why?
| | Plant Proteins | 1 | 1990 | 113 | 0.010 |
Why?
| | Sodium Chloride | 1 | 1990 | 142 | 0.010 |
Why?
| | Receptors, Concanavalin A | 1 | 1989 | 2 | 0.010 |
Why?
| | Lipid Bilayers | 1 | 1990 | 98 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1990 | 390 | 0.010 |
Why?
| | Benzimidazoles | 1 | 1990 | 170 | 0.000 |
Why?
| | Catheterization, Peripheral | 1 | 1990 | 109 | 0.000 |
Why?
| | Confidentiality | 1 | 1990 | 73 | 0.000 |
Why?
| | Mice | 2 | 2001 | 17787 | 0.000 |
Why?
| | Heparin | 1 | 1990 | 261 | 0.000 |
Why?
| | Regression Analysis | 1 | 1991 | 1024 | 0.000 |
Why?
| | Receptors, Cell Surface | 1 | 1989 | 385 | 0.000 |
Why?
| | Antigens, CD | 1 | 1990 | 521 | 0.000 |
Why?
| | Rh Isoimmunization | 1 | 1985 | 3 | 0.000 |
Why?
| | Sex Chromosome Aberrations | 1 | 1985 | 64 | 0.000 |
Why?
| | B-Lymphocytes | 1 | 1990 | 847 | 0.000 |
Why?
| | Models, Biological | 1 | 1990 | 1783 | 0.000 |
Why?
| | Ultrasonography | 1 | 1985 | 759 | 0.000 |
Why?
| | Hemorrhage | 1 | 1985 | 722 | 0.000 |
Why?
| | Mice, Inbred C57BL | 1 | 1990 | 5757 | 0.000 |
Why?
|
|
Ashwood's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|